Skip to main content

Table 2 KRAS and treatment response to Cetuximab-containing regiments in chemotherapy-naïve patients with colorectal carcinoma.

From: Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

Study

Treatments

KRAS

N (%)

RR, N (%)

TTP

(months)

OS

(months)

Remarks

Bokemeyer, 2008

FOLFOX + CTX

WT

61

37 (60.7%)

7.7

NA

KRAS MT has worse RR and TTP.

Cetuximab may have detrimental effects in KRAS MT.

  

MT

52 (46.0%)

17 (32.7%)

5.5

NA

 
 

FOLFOX

WT

73

27 (37.0%)

7.2

NA

 
  

MT

47 (39.2%)

23 (48.9%)

8.6

NA

 

Cervantes, 2008

CTX

WT

29

8 (27.6%)

NA

NA

Patients were treated with CTX first, then in combination with chemo.

KRAS MT has worse RR and TTP.

  

MT

19 (39.6%)

0

NA

NA

 
 

CTX + FOLFIRI

WT

29

16 (55.2%)

9.4

NA

 
  

MT

19 (39.6%)

6 (31.6%)

5.6

NA

 

Punt, 2008

CapOxBev+CTX

WT

153

NA

10.5

22.2

KRAS MT has worse TTP, and OS.

Cetuximab may have detrimental effects in KRAS MT.

  

MT

93 (37.8%)

NA

8.6

19.1

 
 

CapOxBev

WT

152

NA

10.7

23.0

 
  

MT

103 (40.4%)

NA

12.5

24.9

 

Van Custem, 2008

FOLFIRI + CTX

WT

172

102 (59.3%)

9.9

NA

KRAS MT has worse RR and TTP.

Cetuximab may have detrimental effects in KRAS MT.

  

MT

105 (37.9%)

38 (36.2%)

7.6

NA

 
 

FOLFIRI

WT

176

76 (43.2%)

8.7

NA

 
  

MT

87 (33.1%)

35 (40.2%)

8.1

NA

 
  1. Abbreviations: CTX = cetuximab; PAN = panitumumab; IRI = irinotecan; Ox = oxaliplatin; Cap = capcitabine; Bev = bevacizumab; BSC = best supportive care; WT = wild type; MT = mutant type; NA = Not Available or Not Applicable; RR = objective response rate (complete response + partial response); TTP = time to progression; OS = overall survival.